Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): Global pivotal phase 3 study program (STR1VE-US, STR1VE-EU, STR1VE-AP)

This article has no abstract
Epistemonikos ID: d86520fd76ed4ee28c8d4a42fb35745abb321be3
First added on: Feb 11, 2025